Monthly Archives: September 2017

MNG Laboratories Adds the Most Comprehensive Neuropathy Panel to Their Extensive Portfolio of Hereditary Neuropathy Testing

At MNG Laboratories, our goal is to ensure that our test offerings continue to stay at the forefront of genetics. We are excited to announce significant improvements to our neuropathies portfolio.
Our neuropathies portfolio now includes a Comprehensive Neuropathies Panel that includes 629 genes and 14,750 pathogenic variants associated with conditions linked to hereditary neuropathies. This panel includes mtDNA sequencing and deletion analysis, and deletion/duplication of nuclear genes to provide you with the most comprehensive testing possible.
With our Neuropathy portfolio expansion, adding genes doesn’t always mean adding cost. See below for new lower test costs in our Charcot-Marie Tooth portfolio: All of our next-generation sequencing panels include single-exon resolution copy number analysis to provide you the most clinically sensitive testing possible.

Fragile X Repeat Expansion Testing Now Available

At MNG Laboratories, we continuously seek ways to improve our diagnostic abilities and to stay at the forefront of the genetics field. MNG is proud to announce the availability of Fragile X repeat expansion testing within our portfolio of recognized diagnostic tests. We’d also like to recognize this launch in light of July being National Fragile X Awareness Month. You can read more about this at the National Fragile X Foundation’s website. Fragile X is the most common cause of inherited intellectual disability and can be seen in both males and females with a range of symptomatic characteristics. The main cause of Fragile X Syndrome is the repeat expansion region of CGGs in the FMR1 gene resulting in a lack of protein (FMRP) essential for normal cognitive development. The number of repeats correlates to the severity of symptoms, especially in males, and is often linked with Autism Spectrum Disorders. To complement our Fragile X Repeat Expansion testing, MNG includes methylation analysis where clinically relevant. When >200 repeats are discovered, this triggers methylation of FMR1 and stops any synthesis of the fragile X protein, resulting in a complete lack of gene function. While this is a positive feature in females enabling them to use their second healthy copy of FMR1, methylation results in a fully expressed mutation in males and a higher severity of symptoms. Since Fragile X repeat expansions cannot be detected by NGS sequencing alone, we have added Fragile X Repeat Expansion + Methylation Analysis to our Comprehensive Intellectual Disability and X-Linked Intellectual Disability Panels. Our Intellectual Disability portfolio is now better than ever: We strive to give you the best answers possible when you trust us with your patients’ samples. MNG constantly endeavors to provide you with actionable results. Utilizing our proprietary Genome MaNaGer™ pipeline and Neurogenetic Answers™ reporting process, we aim to reduce the distraction of unrelated variants of uncertain significance.

Order Your Next Test

Updates to Selected NGS Panels

MNG Laboratories announces content updates to several next-generation sequencing panels based on recent ClinVar data. All of our NGS panels include copy number analysis in order to provide the most clinically sensitive testing possible. Our complete offering guarantees coverage of all pathogenic variants in the most relevant genes.

Comprehensive Epilepsy Panel

Comprehensive Muscular Dystrophy/Myopathy Panel

 

Comprehensive Intellectual Disabilty Panel

Ataxia/Episodic Ataxia Panel

Spastic Paraplegia Panel

We strive to give you the best answers possible when you trust us with your patients’ samples and endeavor to provide you with actionable results. Utilizing our proprietary Genome MaNaGer™ pipeline and Neurogenetic Answers™ reporting process, we aim to reduce the distraction of unrelated variants of uncertain significance.

NSGC Presentation Announcement

MNG Laboratories will be presentating “Challenging Cases and the Need for Complementary Test Methods to Improve Clinical Sensitivity of Genetic Testing” at this year’s National Society of Genetic Counselor Annual Conference.  
Date and Time:

Wednesday, September 13th 6:30PM-7:00PM

Presenters:

Chief Medical Officer, Dr. Peter L. Nagy, MD, PhD Genetic Counselor, Ymkje Cuperus, MS

Summary:

MNG Laboratories will present multiple case studies in which comprehensive testing methods incorporated into our next-generation sequencing test offerings, such as copy number assessment, mitochondrial genome sequencing with deletion analysis, and repeat expansion testing, can increase clinical sensitivity of genetic testing.